October 30, 2025 | 10:00 - 11:00 AM (PDT) 
Ideas to lND - Your Pathway to Discovery
Empowering Preclinical Innovation
Unlock the full potential of your preclinical research with Cyagen Biosciences. Our integrated solutions span from custom cell and animal model development through preclinical experiments, ensuring every phase of your project is expertly handled. Discover how we can help transform your innovative ideas into actionable outcomes and help translate your research discoveries into INDs.
CTGA Grant
Receive up to $1M in Funding for Custom Model Generation
Explore
Innovative Solutions & Trusted Products
Special Promotions & Discounts
See All Promotions
Award
Cyagen Trailblazer Grant Award – Funding the Frontier of Model Generation
The Cyagen Trailblazer Grant Award (CTGA) 2025 is a global funding initiative supporting breakthroughs in biomedical research through the development of high-impact custom animal models. This year, Cyagen will provide up to $1 million USD in model generation funding to 50 research teams worldwide. Eligible research spans diverse areas, including cancer, neurological, cardiovascular, metabolic, immunological, and rare diseases. Researchers are invited to submit proposals and join an international community driving the future of preclinical research
Explore
Free Trial
Experience Next-Level Humanized Research — Try NKG Mice for Free
Cyagen is inviting researchers in the US and EU to evaluate our NKG mice at no cost. This limited-time offer supports preclinical studies and fosters collaboration within the biomedical research community.
Explore
Special Deal
Research Now, Pay Later: Flexible Funding for Custom Animal Models
We understand that funding delays shouldn’t slow down scientific progress. Our GrantBridge provides flexible payment options to ensure that you can secure your critical research resources now while aligning payment with your funding schedule.
Explore
Your Partners in Preclinical Progress
19
Years of Genetic Innovation
7,000
Global Bioscience Partners
50,000
Mouse & Rat Models Delivered
10,925
SCI Journal Citations
250,000
SPF Animals in AAALAC-Accredited Facilities
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Resource Library
BLOG & INSIGHTS
More Insights
Humanized ABCA4 Models Advance RNA & Gene Editing
Designed for translational research, Cyagen’s B6-hABCA4 and c.5461-10T>C mouse models enable preclinical testing of base editing, antisense oligonucleotides, and RNA editing therapies for Stargardt disease. These models offer precise genomic alignment with human ABCA4 mutations, enhancing clinical relevance.
October 16, 2025
Schedule Meeting
UPCOMING EVENT
More
Frontiers in Cancer Science 2025
Cyagen will be attending Frontiers in Cancer Science 2025 from November 5–7 in Singapore, where our experts will be on hand to discuss your drug development plans and introduce you to our advanced mouse models and comprehensive preclinical research services. We look forward to connecting with you!
Schedule Meeting
WEBINAR
More
Accelerating Glaucoma Drug Discovery: From Preclinical Models to Efficacy Validation
This webinar will introduce how to accelerate ophthalmic drug discovery. Using glaucoma as a case study, it covers preclinical model selection (e.g., OHT, ONC) and efficacy evaluation with in-vivo functional readouts (IOP, OCT, ERG) for therapeutics ranging from small molecules to gene therapies.
Schedule Meeting